Human Oncology & Pathogenesis Program

The Andy Minn Lab

Research

Andy Minn, MD, PhD
Andy Minn, MD, PhD
Lab Head; Chair, Immuno-Oncology Program

In the Minn Lab, we interrogate the intersection of chronic inflammation and interferon signalling, virus mimicry pathways, and immune checkpoint resistance in tumor cells — integrating cellular, molecular and translational approaches. Our goal is to convert mechanistic insights into new therapeutic combinations that potentiate anti-tumor immunity.

Projects

  • Investigate how chronic inflammation and persistent interferon signaling alters local and systemic anti-tumor immunity
  • Discover immunotherapy resistance mechanisms driven by cellular adaptation to chronic inflammation
  • Understand mechanisms of inflammatory “memory” and how it impacts immune responses
  • Explore the role of chronic virus mimicry in immunotherapy response
  • Develop therapeutic strategies targeting immune dysfunction from chronic inflammation
Minn Lab Group

Publications Highlights

Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Langer CJ, Wherry EJ, Minn AJ. Combined JAK Inhibition and PD-1 Immunotherapy for Non Small Cell Lung Cancer Patients. Science. 2024 Jun;384(6702):eadf1329. 

Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, Lihm J, Miriyala J, Sauter JL, Luo J, Chow A, Bhanot UK, McCarthy C, Vanderbilt CM, Liu C, Abu-Akeel M, Plodkowski AJ, McGranahan N, Łuksza M, Greenbaum BD, Merghoub T, Achour I, Barrett JC, Stewart R, Beltrao P, Schreiber TH, Minn AJ, Miller ML, Hellmann MD. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024 Feb 12;42(2):209-224.e9. https://doi.org/10.1016/j.ccell.2023.12.013

View All Publications

People

Andy Minn, MD, PhD

Andy Minn, MD, PhD

Lab Head; Chair, Immuno-Oncology Program

  • The Minn Lab investigates how cancers evolve under chronic inflammation and persistent immune pressure to acquire resistance to immunotherapies, with the goal of developing innovative therapies to restore anti-tumor immunity.
  • MD, PhD, University of Chicago

Members

Ellie Cangialosi
Assistant to Chair, Lab Admin
Nathan Dangle
Graduate Research Assistant
Ivan Kotchetkov
Ivan Kotchetkov
Instructor
Fengshuo Liu
Research Scholar
Vamshidhar Chowdary Nallamala
Bioinformatics Technician
Andrew Ollendorff
Research Technician
Yuwei Qi
Yuwei Qi
Research Scholar
Marco Vincenzo Russo
Lab Manager
Claire Shao
Claire Shao
Research Scholar
Shangshang Wang
Shangshang Wang
Research Scholar

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Andy Minn discloses the following relationships and financial interests:

  • Danger Bio
    Professional Services and Activities (Uncompensated)
  • Dispatch Biotherapeutics
    Equity; Professional Services and Activities (Uncompensated)
  • Xilio Therapeutics, Inc.
    Professional Services and Activities (Uncompensated)

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures